Maturitas · 2026
Adherence to and tolerance of low-dose tamoxifen versus standard-dose tamoxifen in women at increased risk of breast cancer.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pogorelova Mariya O, Buzzard Jennifer A, Fischer Karen M, Salonen Bradley R, Klassen Christine L
Аннотация
OBJECTIVE: Tamoxifen 20 mg daily for 5 years decreases breast cancer (BC) risk by 49% in women with a family history of the disease and by up to 85% in women with a personal history of high-risk lesions. The TAM-01 study demonstrated that patients with ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH) had a 50% reduction in cancer events with 5 mg daily for 3 years. We aimed to determine whether the use of low-dose tamoxifen (LDT) leads to better adherence and tolerance than standard-dose tamoxifen (SDT).
STUDY DESIGN: A retrospective chart review of women with DCIS, LCIS, ADH/ALH, increased risk due to family history of breast cancer, or high-risk gene mutation was performed. Patients were grouped as SDT or LDT. Patients who declined medications were the control.
RESULTS: Among 256 patients, 46% (N = 117) initiated LDT, 21% (N = 55) SDT and 33% (N = 84) declined tamoxifen. 59% of patients on LDT completed 3 years of therapy compared with 47.3% of SDT patients. Five women (2.0%) developed recurrent cancer, and 4 women (1.6%) developed a new malignancy. Vasomotor symptoms were the most commonly reported adverse events, affecting over 40% of patients in both tamoxifen groups.
CONCLUSION: LDT was well tolerated, with a trend toward increased likelihood of completion of therapy. Patients with more than one indication for tamoxifen were more likely to complete therapy. Side-effects were similar in the two treatment groups, although severity was not able to be assessed due to the retrospective study design.
STUDY DESIGN: A retrospective chart review of women with DCIS, LCIS, ADH/ALH, increased risk due to family history of breast cancer, or high-risk gene mutation was performed. Patients were grouped as SDT or LDT. Patients who declined medications were the control.
RESULTS: Among 256 patients, 46% (N = 117) initiated LDT, 21% (N = 55) SDT and 33% (N = 84) declined tamoxifen. 59% of patients on LDT completed 3 years of therapy compared with 47.3% of SDT patients. Five women (2.0%) developed recurrent cancer, and 4 women (1.6%) developed a new malignancy. Vasomotor symptoms were the most commonly reported adverse events, affecting over 40% of patients in both tamoxifen groups.
CONCLUSION: LDT was well tolerated, with a trend toward increased likelihood of completion of therapy. Patients with more than one indication for tamoxifen were more likely to complete therapy. Side-effects were similar in the two treatment groups, although severity was not able to be assessed due to the retrospective study design.